Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Outlook
  • Published:

The further evolution of biotech

Nature Reviews Drug Discovery volume 2, pages 75–79 (2003)Cite this article

Abstract

Born 20 years ago with the launch of recombinant insulin, the biotechnology industry is maturing, with several leading companies now rivalling traditional pharmaceutical companies in many ways. What might the next 20 years hold for biotech-based drug development?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Deals, mergers and acquisitions in the biotechnology industry in the past 10 years.
Figure 2: Increases in the ageing population.
Figure 3: Total health-care and pharmaceutical spending as a percentage of GDP in 2000.

Similar content being viewed by others

References

  1. Berg, C., Nassr, R. & Pang, K. The evolution of biotech. Nature Rev. Drug Discov. 1, 845–846 (2002).

    Article  CAS  Google Scholar 

  2. Decision Resources, Inc., Biotech Alliances 2001: Feeding and Riding the Tiger (Decision Resources, Inc. Spectrum, Pharmaceutical Industry Dynamics, Issue 6, 22 May 2002).

  3. Decision Resources, Inc., Outlook for the European Biotechnology Industry: Industry and Government Cooperation Key to Continued Growth (Decision Resources, Inc. Spectrum, Pharmaceutical Industry Dynamics, Issue 9, 26 June 2002).

  4. Lindpaintner, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nature Rev. Drug Discov. 1, 463–469 (2002).

    Article  CAS  Google Scholar 

  5. Roses, A. D. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541–549 (2002).

    Article  CAS  Google Scholar 

  6. Lesko, L. J. & Woodcock, J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 20–24 (2002).

    Article  CAS  Google Scholar 

  7. Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387–400 (1996).

    Article  CAS  Google Scholar 

  8. Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356 (1997).

    Article  CAS  Google Scholar 

  9. Tang, M. X. et al. The APOE4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279, 751–755 (1998).

    Article  CAS  Google Scholar 

  10. Kardaun, J. W. et al. Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia aging study. Clin. Chem. 46, 1548–1554 (2000).

    CAS  PubMed  Google Scholar 

  11. Graff-Radford, N. R. et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch. Neurol. 59, 594–600 (2002).

    Article  Google Scholar 

  12. Lai, E., Riley, J., Purvis, I. & Roses, A. D. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 54, 31–38 (1998).

    Article  CAS  Google Scholar 

  13. Hewett, D. et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 79, 305–314 (2002).

    Article  CAS  Google Scholar 

  14. McCarthy, L. C. et al. Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics 78, 135–149 (2001).

    Article  CAS  Google Scholar 

  15. Burbaum, J. & Tobal, G. M. Proteomics in drug discovery. Curr. Opin. Chem. Biol. 6, 427–433 (2002).

    Article  CAS  Google Scholar 

  16. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1, 683–695 (2002).

    Article  CAS  Google Scholar 

  17. Lovell-Badge, R. The future for stem cell research. Nature 414, 88–91 (2001)

    Article  CAS  Google Scholar 

  18. Bianco, P. & Gehron Robey, P. Stem cells in tissue engineering. Nature 414, 118–121 (2001).

    Article  CAS  Google Scholar 

  19. United Nations. World population prospects, The 1998 Revision (United Nations, Department of Economic and Social Affairs Population Division, United Nations, New York, 1999).

  20. Organization for Economic Cooperation and Development Health Data (2002) [online] (cited 27 Nov 2002) <http://www.oecd.org/EN/statistics/0,,EN-statistics-12-nodirectorate-no-1-no-12-no-no-2,00.html>.

  21. World Factbook 2001 Publisher (Central Intelligence Agency, Washington DC, USA).

Download references

Author information

Authors and Affiliations

  1. Decision Resources, Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Tricia Nagle, Carilee Berg, Rena Nassr & Kevin Pang

Authors
  1. Tricia Nagle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carilee Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rena Nassr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kevin Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin Pang.

Related links

Related links

DATABASES

Cancer.gov

breast cancer

colon cancer

ovarian cancer

melanoma

uterine cancer

LocusLink

apolipoprotein E

BRCA1

BRCA2

CDKN2A

ERBB2

INSR

MLH1

MSH2

OMIM

Alzheimer's disease

aura-positive migraine

Parkinson's disease

psoriasis

type 2 diabetes

FURTHER INFORMATION

FDA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagle, T., Berg, C., Nassr, R. et al. The further evolution of biotech. Nat Rev Drug Discov 2, 75–79 (2003). https://doi.org/10.1038/nrd989

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd989

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing